Assessment of the Diagnostic Potential of miR-29a-3p and miR-92a-3p as Circulatory Biomarkers in Acute Myeloid Leukemia.

Introduction

Acute myeloid leukemia (AML) comprises a set of myeloproliferative neoplasms, which are characterized by excessive growth of myeloid blasts and production of abnormal, immature blood cells (Jabbour et al., 2006). The prevalence of AML in adults is very high and it is considered the most common type of acute leukemias that occurs in adults (Lowenberg et al., 1999). The malignant transformation of the bone marrow progenitor cells in AML results in abnormal production of poorly differentiated myeloid blasts that interfere with the production of normal and functional blood cells (Lane et al., 2009; Khwaja et al., 2016). Such consequences are responsible for the characteristic symptoms of AML such as fatigue and shortness of breath due to anemia because of lowered production of RBCs, bleeding tendency due to the low number of platelets (Karpatkin, 1969; Psaila et al., 2013), and susceptibility to microbial infections due to the lack of normal functioning leukocytes (Freifeld et al., 2011). The overall survival (OS) of AML patients depends on many factors like the stage of the disease at the time of diagnosis and other health conditions. However, AML follows a rapid progression pattern and exhibit high mortality rates, where patients under the age of 60 years have an OS rate of 30–40%, while the OS is only 10% for the patients who are 60 years or older (Menzin et al., 2002; Majhail et al., 2012).

MicroRNAs, are a class of gene regulators, whose alterations in their expression levels show close association with the onset of many diseases such as cancer. Such relationship is considered a hotspot for research, which motivated many groups to work on expression profiling of miRNAs in different cellular contexts and in different types of neoplasms (Peng and Croce, 2016; Liao et al., 2017; He et al., 2019). Interestingly, each type of leukemia had unique profile of expressed microRNA linked with specific translocation or genetic mutations (Zhang et al., 2009), and such patterns highlighted the potential to use such profiling strategy to discriminate between subtypes of leukemias as well as to predict disease progression (Chan et al., 2011; Pandita et al., 2019). Genes responsible for the production of miRNAs are first transcribed into hairpin structured precursor microRNA molecules, which then are processed to give rise into the mature miRNAs; 19-22-nt long (Bartel, 2004). The regulatory role of the mature miRNAs works through binding to complementary region in target mRNAs, which causes repression of protein translation (Francia et al., 2012).

MicroRNA profiling studies highlighted the potential of such molecules to be used as non-invasive diagnostic / prognostic markers for the detection and monitoring the progression of diseases that may portray a precise image for the underlying pathological conditions (Pogribny, 2018; Tiberio et al., 2015).

Regarding AML, several studies have showed that specific miRNAs profiles associate with different AML subtypes and different cytogenetic abnormalities (Mi et al., 2007). In addition, several microRNAs play roles in leukemogenesis process; acting as oncogenes, which accelerate the onset of malignancy, while others act as tumor suppressor molecules (Svoronos et al., 2016; Bi et al., 2018).

MicroRNA-29 (miR-29) family is a central epigenetic regulators that showed to have a significant role as anti-tumorigenic molecules in different forms of cancer (Iqbal et al., 2012; Li et al., 2017; Tari et al., 2018). Additionally, miR-92a plays a crucial role in the growth of human organs such as heart (Wong et al., 2016), lungs (Zhu et al., 2018) and immune system (Liang et al., 2016) but also the formation of blood vessels (Verma et al., 2019). The circulating levels of mir-92a was found to be elevated in the liver tissue of patients with hepatocellular carcinoma (Shigoka et al., 2010), while low levels of mir-92a were correlated with multiple myeloma (Yoshizawa et al., 2012).

In addition to assessing the levels of microRNAs that are associated with different types of cancers and leukemias, it is mandatory to identify target genes of these microRNA species so we can decipher the pathophysiology of leukemia and identify pathways regulated by miR-29 / miR-92 . Several genetic-based algorithms have been used to identify target genes of miRNAs (Doran and Strauss, 2007). In case of miR-29 , this microRNA family may target many transcription factors and anti-apoptotic genes (Si et al., 2013). Myeloid cell leukemia sequence1 ( MCL1 ) has been identified as a potent target gene of miR-29a and miR-92a (Xu et al., 2014). Mcl-1 belongs to Bcl-2 family which considered an important player in regulation of apoptosis and any change in their expression levels will lead to the progression of human cancer (Thomas et al., 2010; Kadia et al., 2019). In addition, MCL1 functions in leading miR-29 targets into multiple cell types (Mott et al., 2007; Xiong et al., 2010) and miR-29a targets MCL1, which act as an anti-apoptotic transducer in primary AML samples (Garzon et al., 2009).

Therefore, identifying AML-specific microRNA species will help in the diagnosis of AML patients and their levels may correlate with AML pathogenesis and suggests a potential role played by these molecules in disease control. Such strategy could be achieved by quenching oncogenic miRNAs or upregulating pro-apoptotic species, via the transfection of synthetic RNA oligonucleotides representing the anti-sense or sense strands of target miRNAs, respectively (Marcucci et al., 2011).

Materials and Methods

Patient Criteria

To study the modulation of microRNAs levels in AML patients, 40 newly diagnosed AML patients were enrolled in this study (14 males and 26 females, who have not received any treatment at the time of enrollment in the study; Age range 21-68), in addition to control group, which comprised of 20 healthy subjects (10 males and 10 females; Age range 19-69). The diagnosis of AML was based on the new WHO Classification based on FAB morphological subtypes and Immunophenotyping done by flow cytometry. Cytogenetic analysis was performed to detect chromosomal translocations. Mutation analysis using PCR were done to detect the presence of Internal Tandem Duplications (ITD) in FMS- like tyrosine kinase 3 (FLT3) gene. All patients were informed of the details of the research and signed a written consent. This study was approved by the Ethical Committee of the National Cancer Institute, Cairo University Sample Collection, Extraction of total RNA and MicroRNAs and Reverse Transcription:

Bone marrow aspiration samples and peripheral blood samples were collected from patients along with blood samples from control subjects. Plasma samples were separated from blood cells by centrifugation, transferred to separate tubes and stored at -80ºC until used for microRNAs extraction. Blood cell pellets were subjected to RBCs lysis buffer (5mm MgCl2,10mm NaCl, 10mm Tris-HCl, pH7.0; Promega, USA). The remaining leukocytes were used for total RNA extraction using Trizol reagent (ThermoFisher, USA). Total RNA samples were reverse-transcribed into cDNA using RevertAid First Strand cDNA synthesis kit (ThermoFisher, USA) following the manufacturer’s recommended instructions. The cDNA samples were used as templates to quantitatively analyze the transcript level of the target gene (MCL1 ). On the other hand, circulating mature miRNAs was isolated from plasma using miRNAeasy kit (Qiagen, Germany), which were then reverse transcribed using the miScript II RT KIT (Qiagen, Germany).

Quantitative polymerase chain reaction (qPCR)

All primers used in the study were synthesized and HPLC – purified (Eurofins, Germany; Table 1 ).

QPCR assay for microRNAs

Primer sequences used for miRNAs analysis were retrieved from miRbase database. Real time PCR was used to detect miR29a-3p and mir-92a-3p levels using miScript SYBR green PCR kit (Qiagen, Germany) according to manufacturers’ recommendations. The thermal amplification profile was set as following; at 95°C for 5 min as initial denaturation step, followed by 94°C for 15 s, 55°C for 30s, and 70°C for 30s for 50 cycles. At the end of the PCR cycles, products’ melt curve data were collected. Expression levels of miRNAs were normalized to mir-16-5P.

QPCR assay for the target gene

Structures of primers used for MCL1 target gene analysis ( Table 2 ) were checked using Oligo Analyzer Software (Integrated DNA technologies, USA). In primers design, we considered to permit specific amplification and to avoid amplification off contaminating genomic DNA or formation of self-dimers, hairpin structures or heterodimers were Primers were synthesized and subjected to HPLC purification (Eurofins, Germany).Amplification of MCL1 target gene was carried out by using SYBR green dye (GoTaq qPCR master mix; Promega, USA) along with amplification of GAPDH as a house keeping gene. The total volume of the PCR Reactions was 20 µl containing 3 μl of 1:30 diluted cDNA sample (equivalent to 5 ng total RNA), 10μl 2X GoTaq ® qPCR Master Mix (Promega), 0.25 pmole, each of forward and reverse primers, and nuclease free water was added to bring the volume to 20 µl. All reactions were performed in duplicate and the reactions that showed inconsistency between the duplicates were repeated. The thermal profile Started with denaturation at 95°C for 5 min, followed by 50 cycles of 95°C for 15 s, 60°C for 30 s, and 72°C for 30 s. At the end of the PCR cycles, melt curves of the amplicons were obtained. In order to verify the amplification of correct products, PCR reactions were separated onto 1.5% agarose gel electrophoresis.

Data analysis

The relative quantification (RQ) of the target gene expression was calculated using comparative CT method (2 -ΔΔCT ) where ΔΔCT is the difference between ΔCT values of the leukemia patient and that of the control group (ΔΔCT = Ct target -Ct reference ) AML sample -(Ct target -Ct reference ) Control sample.

Statistical analysis

Data was analyzed using SPSS software version 16 (SPSS Inc., Chicago, IL). Qualitative data were described using numbers and percentages. Quantitative data were described using median, mean and standard deviation. Comparisons between numerical variables of two groups were done by unpaired student’s t test for parametric data, Kruskal-Wallis Test was used to compare more than two groups for qualitative variables Correlation analysis: Pearson coefficient where the sign of the coefficient indicates whether the relation is positive or negative, while the value indicates the strength of the correlation as follows: weak correlation: r <0.25, intermediate correlation: 0.25-0.74 and strong correlation: 0.75-0.99 All statistical tests were two-sided, and P values less than 0.05 were considered as statistically significant.

Results

Data presented in this study were obtained from the analysis of samples collected from 40 AML patients who were referred to the department of clinical pathology between February 2013 to October 2014. In this study, the median age of patient was 46 years. A total of 20 healthy individuals with a median age of 27 years served as the control group. In our study we used peripheral blood or bone marrow samples with significant percentage of myeloid blasts. Samples were assayed to quantify the circulating levels of miR-29a-3p , and miR-92a-3p and the transcript level of MCL1 in leukocytes by real-time PCR.

Hematological data

Complete Blood count (CBC) was performed for all subjects enrolled in this study. The CBC revealed that all the AML patients suffered from severe anemia with significant reduction in Hb levels (p<0.001) (Hb ranged from 2.9-10.4 g / dl with a mean value of 7.35±1.87 g / dl. The Hb of the control group, on the other hand, ranged from 11.1-15.3 g / dl with a mean value of 12.60±1.46 g / dl. Regarding the Total Leucocytic count (TLC), data of AML patients ranged from 11.5-150.1 X10 9 /L with a mean value of 80.9±69.2 X10 9 /L, while the control group ranged from 3.3-6.4 X 10 9 /L with a mean value of 5.21±1.18 (p < 0.001). Platelet counts (PLT) also showed significant decrease in AML patients with a mean value of 37.32-38.43 X10 9 /L, while in the control group had higher levels with a mean value of 250 X10 9 /L. There is a statistically significant decrease in platelet count as compared to the control group, (p <0.001). The detailed hematologic data of AML patients are presented in Table 3 .

Morphological Analysis, Immunophenotyping, Cytogenetic Analysis and FLT3 mutations

Bone marrow aspiration was obtained from all the patients enrolled in this study, and classification of the AML cases performed by using the FAB criteria based on morphological and cytochemical picture (M0 to M7). For morphologic inspection, blood smears were Leishman-stained analyzed. For Flow Cytometry, Bone marrow aspirates or Peripheral Blood samples were collected for surface antigen staining using different monoclonal antibodies. There was a heterogeneity in FAB subtypes in this study (data shown in Table 4 ). Standard cytogenetic analysis was performed to detect chromosomal abnormalities, where our data showed that 33 patients had normal karyotype while 7 patients had chromosomal translocations (Data shown in table 4 ). Also, in this study, Genomic DNA was screened for the presence of mutational events in the cytoplasmic region of FLT3 receptor. Internal tandem duplications in FLT3 (FLT3-ITD) was found in 9 patients while the rest 31 cases were negative for FLT3-ITD.

Expression levels of circulating mir-29a-3p and mir-92a-3p in AML patients

Compared to normal controls, miR-29a-3p circulating levels in the plasma of adult AML patients were significantly decreased (p < 0.001, Figure 1 ); this reduction was observed in 90% of the patients. Similarly, the plasma mir-92a-3p level in the patients were dramatically decreased when compared to that in healthy controls (p < 0.001, Figure 2 ); 100% of the patients had low levels of circulating mir-92a-3p. Using Spearman’s correlation, data analysis showed that the expression levels of circulating mir-29a-3p and mir-92a-3p in AML patient was almost the same as the patients’ bone marrow samples. Moreover, there was a statistically significant positive direct correlation between expression of mir-29a and mir-92a (R=0.533, p = 0.001) ( Figure 6 ).

Correlations between plasma levels of mir-29a-3p/mir-92a-3p and clinical picture

In this study, we investigated the correlation between plasma levels of mir-29a-3p / mir-92a-3p with the clinical characteristics of adult AML patients. Regarding miRNA 29a-3p , there was no correlation between miRNA 29a-3p levels and age, TLC, PLT, cytogenetic abnormalities and FLT3 mutations. However, there was a clear significant correlation between miRNA 29a-3p and sex as its levels were markedly higher in female patients compared to males (p =0.014). Additionally, mir29a-3p expression was significantly downregulated in patients expressing CD13 (p =0.02). Regarding miRNA 92a-3p , there was no correlation between miRNA 92a-3p levels and age, sex, or hematological parameters (Hb, TLC and PLT).

Expression levels of the target gene MCL1 in acute myeloid leukemia

To clarify the mechanisms underlying the roles of miR-29a-3p and mir-92a-3p , public miRNA databases. miRDB was scanned to predict the potential target of miR-29a-3p and mir-92a-3p . As indicated in Figure 3 , the 3′-UTR of MCL1 contains a binding site for both microRNAs. To confirm this relationship, we assessed the expression levels of MCL1 in blood cells of AML patients. The data analysis revealed that MCL1 exhibited altered expression in 95% of the patients compared to the healthy control group. The majority of the patients (77.5%) had increased levels of MCL1 transcripts, 17.5% of the patients showed slight downregulation in MCL1 levels, while the rest of the patients (5%) had comparable values to that of the control group. The elevation of RQ values of MCL1 gene transcript in the AML patients was highly significant, p < 0.001 ( Figure 4 ). There was no correlation between Mcl-1 expression and age, sex, TLC, PLT, BM blasts or any of the immunophenotypic markers. Regarding cytogenetic analysis, 82.5% of AML patients are within the group of the intermediate risk with Normal Karyotype (33 patients) of which 25 showed the highest statistically significant expression of MCL1 (p <0.001), Table 4 . However, the data analysis revealed that Mcl-1 expression was significantly decreased in patients with low Hb concentration (p =0.01). Interestingly, the correlation analysis showed a negative correlation between both mir-29a-3p and mir-92a-3p levels and MCL1 RQ values in AML patients (R= -0.606, p < 0.001, R= -0.339, p = 0.043, Respectively) ( Figure 5 ).

Discussion

AML is one of the most aggressive hematopoietic malignancies that initiates at the bone marrow and leads to the aberrant production of blood cells (Dohner et al., 2010). Searching for novel markers for the early detection of AML onset is mandatory for disease management and to allow initiation of the recommended treatment, which would improve the patients’ quality of life and help in achieving complete remission or increase the overall survival of patients (Bai et al., 2013). Liquid biopsies represented by body fluids provide an important source of circulating non-invasive cancer biomarkers that can be utilized instead of the expensive and invasive traditional diagnostic methods (Palmirotta et al., 2018). Among these markers miRNAs, which act as gene regulators and their abnormal expression and dysregulation is common in many diseases and thus, they can be used for detecting pathological conditions (Soifer et al., 2007; Cui et al., 2019; Liu et al., 2019).

The aim of our study was to assess the potential role of plasma miR29a and miR-92a levels as diagnostic and/or prognostic markers for detection of the onset and/or progression of AML in adult patients. In addition, we tried to find the clinical and prognostic implications of miR29a and miR-92a dysregulation. In the meantime, we aimed to validate the regulatory role of miR29a and miR-92a on the oncogenic gene, MCL1 .

Bone marrow and Peripheral blood samples were collected from patients enrolled in this study, and microRNAs were extracted and quantified using Real-Time PCR using specific mir29a-3p and mir92a-3p primers. We observed that there is a significant downregulation of mir29a-3p and mir92a-3p in the bone marrow aspirates and the plasma of the newly diagnosed AML patients when compared to normal subjects; (p <0.001). Similar Results were reported by other study groups (Zhu et al., 2013; Gong et al., 2014; Xu et al., 2014) who reported a downregulation in miR-29a/29b levels in peripheral blood mononuclear cells and bone marrow from AML patients compared with healthy individuals. Also, miR-29a was found to be downregulated in many other types of neoplasms like lung cancer (Barkley and Santocanale, 2013), oral squamous carcinoma (Lu et al., 2014), glioblastoma (Xi et al., 2017), metastatic prostate cancer (Ahmed et al., 2013), ALK-positive anaplastic large cell lymphomas (Desjobert et al., 2011), endocrine-sensitive breast cancer (Muluhngwi et al., 2017).

This downregulation of mir29a is attributed to its function, which was demonstrated to play an important role in inducing apoptosis process in the cells. This downregulation is usually reached through regulation of methylation. In our study we found that mir-29a downregulation will lead to the overexpression of MCL1 , an anti-apoptotic gene that helps in survival of cancer cells and inhibits apoptosis (Gong et al., 2014). MC11 is one of the markers that always found to be associated with the pathogenesis of leukemia and also is implicated in the drug resistance process and relapse in AML (Pan et al., 2015). After Investigating the expression of MCL1 using qPCR, we detected that the majority of the patients (31/40, 77.5%) had upregulated MCL1 . Mir-29 has the ability to suppress the anti-apoptotic ability of the cells through negative regulation of the oncogenic Matrix-Metalloproteinase 2 (MMP-2) gene (Li and Li, 2013). Moreover, the absence of miR-29a will lead to the aberrant upregulation of HSP60, a member of heat shock proteins family, and downregulating other members like HSP27/40/70/90 in breast cancer as reported by Choghaei et al., (2016). In addition to the role of miR-29a in inducing apoptosis, it also functions as angiogeneic inhibitor which is required for malignant neoplasms. Mir-29a regulates and suppresses the expression of vasohibin 2 (VASH2); one of the angiogenic factors (Jia et al., 2016). Interestingly, previous studies reported that treatment of leukemia with miR-29a prevents the proliferation of myeloid blasts (Garzon et al., 2009; Han et al., 2010; Amodio et al., 2015).

On the contrary, some studies showed that AML patients had an elevated level of miR-29a (Wang et al., 2012). Many reports showed that over expression of miR-29a will lead to increased cellular proliferation through suppressing the expression of Mucin1, as well as regulating MAPK and β-catenin pathways (Trehoux et al., 2015). Another study by Han et al., (2010) showed that overexpression of miR-29a in blood cells resulted in the onset of myeloproliferative neoplasms that can be developed to give AML. In addition, miR-29a mediates progenitor cells proliferation by accelerating the transition of G1 phase to S/G2 phase (Amodio et al., 2015). Furthermore, different members of miR-29 family were overexpressed in sera of patients with osteosarcoma, colorectal cancer (Huang et al., 2010; Brunet Vega et al., 2013) and in metastatic-liver carcinoma (Wang and Gu, 2012) as well as in breast cancer (Wu et al., 2012).

In addition to mir-29a quantification, we also estimated the levels of plasma mir-92a-3p in AML patients, and the data analysis revealed that there is an obvious downregulation in the level of this microRNA species compared to healthy subjects (p < 0.001). As reported previously, in AML cell lines, miR-92a was remarkably downregulated and consequently leads to the over-expression of Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) leading to increasing in the propagation and survival of malignant cells (Gu et al., 2017) .

Our results are in accordance with many other studies (Tanaka et al., 2009; Elhamamsy et al., 2017) who reported that mir-92a plasma levels were significantly lower in AML patients and also it was found to be very low in tumor tissues retrieved from patients with gastric cancer (Zhao et al., 2018), However, other studies found that suppression of miR-92a will induce apoptosis and can be considered as a novel method for treatment of Acute Promyelocytic Leukemia (Sharifi et al., 2014). Also, upregulation in miR-92a was observed in colorectal cancer (Elshafei et al., 2017) and cervical cancer (Zhou et al., 2015; Kawai et al., 2018).

In our study we could not find significant correlation between the levels of mir29a-3p and mir92a-3p expression and AML-subtypes, however, Zhu et al., (2013) studied the association of miR-29a levels in pediatric acute leukemia and they found that miR-29a was downregulated in AML-M7 compared to other subtypes (p <0.001). However, one of our future perspectives is to increase the sample size and recruit more patients with various AML-subtypes which may help in establishing a real subtype-dependent relationship. The authors evaluated the levels of miR-29a in patients with different cytogenetic analysis and they found that high miR-29a levels were detected among patients with favorable karyotypes (Zhu et al., 2013). Similarly, El-Halawani et al., (2017) found that the mir92a levels were significantly lower in the poor risk cytogenetics as compared to the favorable and intermediate risk cytogenetics. In addition to the lack of correlation of the tested miRNAs with subtypes and karyotypes, we also could not find significant relationship with FLT3-ITD. However, El-Halawani et al., (2017) reported high level of miRNA29a expression in Flt3-ITD+ as compared to the Flt3-ITD. Moreover, the correlation analysis revealed the presence of significant positive direct association between levels of mir-29a and mir-92a (r=0.533, p = 0.001) and negative correlation with MCL1 transcript level was observed (r= -0.606, p<0.001, r= -0.339, p=0.043, respectively) and this was consistent with other studies that showed that down-regulation of miR-29a and miR-29b accompanied by up-regulation of the anti-apoptotic gene MCL1 transcripts as well as Bcl 2 in myeloid leukemias and such increase reflects poor prognosis (Li et al., 2019). In our study, no relationship was found between Mcl-1 expression and age, sex, TLC, PLT, BM blasts, cell surface antigens or FLT3-ITD. However, Mcl-1 expression showed a considerable decrease in patients with low Hb concentration and in patients with Normal karyotype (p<0.05 and 0.01, respectively).

In conclusion, we investigated the circulating levels of mir-29a-3p/mir-92a-3p in AML patients and we found that both species were downregulated in the patients’ plasma and they are negatively correlated with their target gene MCL1 transcript levels. The data proved our hypothesis that mir-29a and mir-92a act as anti-tumorigenic molecules and highlighted their potential as promising non-invasive diagnostic biomarker for AML that can be utilized in the future as candidates for therapeutic intervention.

Acknowledgments

N/A.

Funding Details

The authors received no specific funding for this work

Ethical Statement

This study was approved by the Ethical Committee of National Cancer Institute, Cairo University.

Conflict of Interest

The authors have no conflict of interest to declare

References

Ahmed F Shiraishi T Vessella RL Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a Oncol Rep 2013 30 2963 8 24100420 10.3892/or.2013.2789

Amodio N Rossi M Raimondi L miR-29s: a family of epi-miRNAs with therapeutic implications in hematologic malignancies Oncotarget 2015 6 12837 61 25968566 10.18632/oncotarget.3805 PMC4536984

Bai J He A Zhang W Potential biomarkers for adult acute myeloid leukemia minimal residual disease assessment searched by serum peptidome profiling Proteome Sci 2013 11 39 23915341 10.1186/1477-5956-11-39 PMC3751134

Barkley LR Santocanale C MicroRNA-29a regulates the benzo[a]pyrene dihydrodiol epoxide-induced DNA damage response through Cdc7 kinase in lung cancer cells Oncogenesis 2013 2 e57 23877787 10.1038/oncsis.2013.20 PMC3740286

Bartel DP MicroRNAs: genomics, biogenesis, mechanism, and function Cell 2004 116 281 97 14744438 10.1016/s0092-8674(04)00045-5

Bi L Sun L Jin Z MicroRNA-10a/b are regulators of myeloid differentiation and acute myeloid leukemia Oncol Lett 2018 15 5611 9 29552198 10.3892/ol.2018.8050 PMC5840650

Brunet Vega A Pericay C Moya I microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers Oncol Rep 2013 30 320 6 23673725 10.3892/or.2013.2475

Chan E Prado DE Weidhaas JB Cancer microRNAs: from subtype profiling to predictors of response to therapy Trends Mol Med 2011 17 235 43 21354374 10.1016/j.molmed.2011.01.008 PMC3092835

Choghaei E Khamisipour G Falahati M Knockdown of microRNA-29a changes the expression of heat shock proteins in breast carcinoma MCF-7 cells Oncol Res 2016 23 69 78 10.3727/096504015X14478843952906 PMC7842558 26802653

Cui M Wang H Yao X Circulating MicroRNAs in Cancer: Potential and challenge Front Genet 2019 10 626 31379918 10.3389/fgene.2019.00626 PMC6656856

Desjobert C Renalier MH Bergalet J MiR-29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression Blood 2011 117 6627 37 21471522 10.1182/blood-2010-09-301994

Dohner H Estey EH Amadori S Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 2010 115 453 74 19880497 10.1182/blood-2009-07-235358

Doran J Strauss WM Bio-informatic trends for the determination of miRNA-target interactions in mammals DNA Cell Biol 2007 26 353 60 17504030 10.1089/dna.2006.0546

Elhamamsy AR El Sharkawy MS Zanaty AF Circulating miR-92a, miR-143 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia Int J Mol Cell Med 2017 6 77 86 28890884 10.22088/acadpub.BUMS.6.2.2 PMC5581549

Elshafei A Shaker O Abd El-Motaal O The expression profiling of serum miR-92a, miR-375, and miR-760 in colorectal cancer: An Egyptian study Tumour Biol 2017 39 1010428317705765 28618945 10.1177/1010428317705765

Francia S Michelini F Saxena A Site-specific DICER and DROSHA RNA products control the DNA-damage response Nature 2012 488 231 5 22722852 10.1038/nature11179 PMC3442236

Freifeld AG Bow EJ Sepkowitz KA Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America Clin Infect Dis 2011 52 427 31 21205990 10.1093/cid/ciq147

Garzon R Heaphy CE Havelange V MicroRNA 29b functions in acute myeloid leukemia Blood 2009 114 5331 41 19850741 10.1182/blood-2009-03-211938 PMC2796138

Gong JN Yu J Lin HS The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia Cell Death Differ 2014 21 100 12 24076586 10.1038/cdd.2013.133 PMC3857615

Gu Y Si J Xiao X miR-92a inhibits proliferation and induces apoptosis by regulating methylenetetrahydrofolate dehydrogenase 2 (MTHFD2) expression in acute myeloid leukemia Oncol Res 2017 25 1069 79 28059050 10.3727/096504016X14829256525028 PMC7841081

Han YC Park CY Bhagat G microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia J Exp Med 2010 207 475 89 20212066 10.1084/jem.20090831 PMC2839143

He C Luo B Jiang N OncomiR or antioncomiR: Role of miRNAs in acute myeloid leukemia Leuk Lymphoma 2019 60 284 94 30187809 10.1080/10428194.2018.1480769

Huang Z Huang D Ni S Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer Int J Cancer 2010 127 118 26 19876917 10.1002/ijc.25007

Iqbal J Shen Y Liu Y Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis Blood 2012 119 4939 48 22490335 10.1182/blood-2011-07-370122 PMC3367895

Jabbour EJ Estey E Kantarjian HM Adult acute myeloid leukemia Mayo Clin Proc 2006 81 247 60 16471082 10.4065/81.2.247

Jia P Cai H Liu X Long non-coding RNA H19 regulates glioma angiogenesis and the biological behavior of glioma-associated endothelial cells by inhibiting microRNA-29a Cancer Lett 2016 381 359 69 27543358 10.1016/j.canlet.2016.08.009

Kadia TM Kantarjian HM Konopleva M Myeloid cell leukemia-1 dependence in acute myeloid leukemia: a novel approach to patient therapy Oncotarget 2019 10 1250 65 30815228 10.18632/oncotarget.26579 PMC6383813

Karpatkin S Heterogeneity of human platelets Metabolic and kinetic evidence suggestive of young and old platelets J Clin Invest 1969 48 1073 82 5771188 10.1172/JCI106063 PMC322321

Kawai S Fujii T Kukimoto I Identification of miRNAs in cervical mucus as a novel diagnostic marker for cervical neoplasia Sci Rep 2018 8 7070 29728572 10.1038/s41598-018-25310-1 PMC5935744

Khwaja A Bjorkholm M Gale RE Acute myeloid leukaemia Nat Rev Dis Primers 2016 2 16010 27159408 10.1038/nrdp.2016.10

Lane SW Scadden DT Gilliland DG The leukemic stem cell niche: current concepts and therapeutic opportunities Blood 2009 114 1150 7 19401558 10.1182/blood-2009-01-202606 PMC2723012

Li L Li H Role of microRNA-mediated MMP regulation in the treatment and diagnosis of malignant tumors Cancer Biol Ther 2013 14 796 805 23917402 10.4161/cbt.25936 PMC3909548

Li XX Zhou JD Wen XM Increased MCL-1 expression predicts poor prognosis and disease recurrence in acute myeloid leukemia Onco Targets Ther 2019 12 3295 304 31118680 10.2147/OTT.S194549 PMC6503339

Li Y Wang Z Li Y MicroRNA-29a functions as a potential tumor suppressor through directly targeting CDC42 in non-small cell lung cancer Oncol Lett 2017 13 3896 904 28521487 10.3892/ol.2017.5888 PMC5431235

Liang DY Hou YQ Luo LJ Altered expression of miR-92a correlates with Th17 cell frequency in patients with primary biliary cirrhosis Int J Mol Med 2016 38 131 8 27246196 10.3892/ijmm.2016.2610 PMC4899017

Liao Q Wang B Li X miRNAs in acute myeloid leukemia Oncotarget 2017 8 3666 82 27705921 10.18632/oncotarget.12343 PMC5356910

Liu Y Cheng Z Pang Y Role of microRNAs, circRNAs and long noncoding RNAs in acute myeloid leukemia J Hematol Oncol 2019 12 51 31126316 10.1186/s13045-019-0734-5 PMC6534901

Lowenberg B Downing JR Burnett A Acute myeloid leukemia N Engl J Med 1999 341 1051 62 10502596 10.1056/NEJM199909303411407

Lu L Xue X Lan J MicroRNA-29a upregulates MMP2 in oral squamous cell carcinoma to promote cancer invasion and anti-apoptosis Biomed Pharmacother 2014 68 13 9 24210072 10.1016/j.biopha.2013.10.005

Majhail NS Brazauskas R Hassebroek A Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia Biol Blood Marrow Transplant 2012 18 861 73 22040843 10.1016/j.bbmt.2011.10.031 PMC3288160

Marcucci G Mrozek K Radmacher MD The prognostic and functional role of microRNAs in acute myeloid leukemia Blood 2011 117 1121 9 21045193 10.1182/blood-2010-09-191312 PMC3056468

Menzin J Lang K Earle CC The outcomes and costs of acute myeloid leukemia among the elderly Arch Intern Med 2002 162 1597 603 12123403 10.1001/archinte.162.14.1597

Mi S Lu J Sun M MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia Proc Natl Acad Sci U S A 2007 104 19971 6 18056805 10.1073/pnas.0709313104 PMC2148407

Mott JL Kobayashi S Bronk SF mir-29 regulates Mcl-1 protein expression and apoptosis Oncogene 2007 26 6133 40 17404574 10.1038/sj.onc.1210436 PMC2432524

Muluhngwi P Krishna A Vittitow SL Tamoxifen differentially regulates miR-29b-1 and miR-29a expression depending on endocrine-sensitivity in breast cancer cells Cancer Lett 2017 388 230 8 27986463 10.1016/j.canlet.2016.12.007 PMC5318263

Palmirotta R Lovero D Cafforio P Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology Ther Adv Med Oncol 2018 10 1758835918794630 30181785 10.1177/1758835918794630 PMC6116068

Pan R Ruvolo VR Wei J Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia Blood 2015 126 363 72 26045609 10.1182/blood-2014-10-604975 PMC4504949

Pandita A Ramadas P Poudel A Differential expression of miRNAs in acute myeloid leukemia quantified by Nextgen sequencing of whole blood samples PLoS One 2019 14 e0213078 30893351 10.1371/journal.pone.0213078 PMC6426230

Peng Y Croce CM The role of MicroRNAs in human cancer Signal Transduct Target Ther 2016 1 15004 29263891 10.1038/sigtrans.2015.4 PMC5661652

Pogribny IP MicroRNAs as biomarkers for clinical studies Exp Biol Med (Maywood) 2018 243 283 90 28914096 10.1177/1535370217731291 PMC5813862

Psaila B Bussel JB Frelinger AL Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal J Thromb Haemost 2013 11 1002 3 23496753 10.1111/jth.12191

Sharifi M Salehi R Gheisari Y Inhibition of microRNA miR-92a induces apoptosis and necrosis in human acute promyelocytic leukemia Adv Biomed Res 2014 3 61 24627869 10.4103/2277-9175.125826 PMC3950842

Shigoka M Tsuchida A Matsudo T Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development Pathol Int 2010 60 351 7 20518884 10.1111/j.1440-1827.2010.02526.x

Si H Sun X Chen Y Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer J Cancer Res Clin Oncol 2013 139 223 9 23052693 10.1007/s00432-012-1315-y PMC3549412

Soifer HS Rossi JJ Saetrom P MicroRNAs in disease and potential therapeutic applications Mol Ther 2007 15 2070 9 17878899 10.1038/sj.mt.6300311

Svoronos AA Engelman DM Slack FJ OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer Cancer Res 2016 76 3666 70 27325641 10.1158/0008-5472.CAN-16-0359 PMC4930690

Tanaka M Oikawa K Takanashi M Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients PLoS One 2009 4 e5532 19440243 10.1371/journal.pone.0005532 PMC2678255

Tari K Shamsi Z Reza Ghafari H The role of the genetic abnormalities, epigenetic and microRNA in the prognosis of chronic lymphocytic leukemia Exp Oncol 2018 40 261 7 30593759

Thomas LW Lam C Edwards SW Mcl-1; the molecular regulation of protein function FEBS Lett 2010 584 2981 9 20540941 10.1016/j.febslet.2010.05.061

Tiberio P Callari M Angeloni V Challenges in using circulating miRNAs as cancer biomarkers Biomed Res Int 2015 2015 731479 25874226 10.1155/2015/731479 PMC4385632

Trehoux S Duchene B Jonckheere N The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways Biochem Biophys Res Commun 2015 456 757 62 25511698 10.1016/j.bbrc.2014.12.025

Verma M Asakura Y Asakura A Inhibition of microRNA-92a increases blood vessels and satellite cells in skeletal muscle but does not improve duchenne muscular dystrophy-related phenotype in mdx mice Muscle Nerve 2019 59 594 602 30698289 10.1002/mus.26433 PMC8710231

Wang LG Gu J Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis Cancer Epidemiol 2012 36 e61 7 22018950 10.1016/j.canep.2011.05.002

Wang XS Gong JN Yu J MicroRNA-29a and microRNA-142-3p are regulators of myeloid differentiation and acute myeloid leukemia Blood 2012 119 4992 5004 22493297 10.1182/blood-2011-10-385716

Wong LL Wang J Liew OW MicroRNA and heart failure Int J Mol Sci 2016 17 502 27058529 10.3390/ijms17040502 PMC4848958

Wu Q Wang C Lu Z Analysis of serum genome-wide microRNAs for breast cancer detection Clin Chim Acta 2012 413 1058 65 22387599 10.1016/j.cca.2012.02.016

Xi Z Wang P Xue Y Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6 Oncotarget 2017 8 24949 63 28212562 10.18632/oncotarget.15327 PMC5421901

Xiong Y Fang JH Yun JP Effects of microRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma Hepatology 2010 51 836 45 20041405 10.1002/hep.23380

Xu L Xu Y Jing Z Altered expression pattern of miR-29a, miR-29b and the target genes in myeloid leukemia Exp Hematol Oncol 2014 3 17 25006537 10.1186/2162-3619-3-17 PMC4086441

Yoshizawa S Ohyashiki JH Ohyashiki M Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders Blood Cancer J 2012 2 e53 22829237 10.1038/bcj.2011.51 PMC3270255

Zhang H Luo XQ Zhang P MicroRNA patterns associated with clinical prognostic parameters and CNS relapse prediction in pediatric acute leukemia PLoS One 2009 4 e7826 19915715 10.1371/journal.pone.0007826 PMC2773830

Zhao X Hou Y Tuo Z Application values of miR-194 and miR-29 in the diagnosis and prognosis of gastric cancer Exp Ther Med 2018 15 4179 84 29725366 10.3892/etm.2018.5931 PMC5920402

Zhou C Shen L Mao L miR-92a is upregulated in cervical cancer and promotes cell proliferation and invasion by targeting FBXW7 Biochem Biophys Res Commun 2015 458 63 9 25623537 10.1016/j.bbrc.2015.01.066

Zhu C Wang Y Kuai W Prognostic value of miR-29a expression in pediatric acute myeloid leukemia Clin Biochem 2013 46 49 53 22981932 10.1016/j.clinbiochem.2012.09.002

Zhu Q Zang Q Jiang ZM Enhanced expression of non coding miR 92a expression is implicated in the development of lung cancer Eur Rev Med Pharmacol Sci 2018 22 1028 34 29509251 10.26355/eurrev_201802_14385